Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

INTRODUCTION: Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor that has demonstrated antitumour activity and an acceptable safety profile in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer and other solid tumours. METHODS: This was a phase I/I...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, L W-C, Xu, B, Gupta, S, Freyman, A, Zhao, Y, Abbas, R, Vo Van, M-L, Bondarenko, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670493/
https://www.ncbi.nlm.nih.gov/pubmed/23632474
http://dx.doi.org/10.1038/bjc.2013.178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670493/
https://www.ncbi.nlm.nih.gov/pubmed/23632474
http://dx.doi.org/10.1038/bjc.2013.178

Ejemplares similares